Hikma Pharmaceuticals PLC has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc., part of the Boehringer Ingelheim. The companies had previously agreed to the acquisition in  July 2014.

The Ben Venue site includes four manufacturing plants and a Quality and Development Center (QDC). The QDC, which includes a R&D pilot plant, will strengthen Hikma’s existing R&D capabilities and support the development of its pipeline. The four manufacturing plants are not currently in use. Hikma will transfer certain modern, advanced equipment to  increase capacity at its other manufacturing facilities in the United States and Europe.

See related story, “M&A Heats Up in the  Global Injectables Market.”

Source: Hikma